ABT - CIK 0000001800
The table below shows ABBOTT LABORATORIES's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B | $7.90B |
| Capital expenditure | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B | $2.18B |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | -$2.01B | -$2.21B |
| Dividends paid | - | - | - | - | - | - |
ABBOTT LABORATORIES reported operating cash flow of $9.57B for fiscal year 2025. That is up 11.8% from $8.56B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $3.20B (FY 2016) to $9.57B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $893.00M | $1.29B | $1.23B | $3.79B | $2.30B | $403.00M |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | -$5.49B | -$2.78B |